

Special Issue on  
**Regulation of Type 2 Immune Responses by Myeloid Cells**

# CALL FOR PAPERS

Type 2 immune responses can contribute to host defense against parasites and venoms, but can also drive pathology associated with allergic disorders. Thus, type 2 responses must be tightly regulated to mount protective responses yet preserve homeostasis and avoid immunopathology. Increase in tissue mast cell numbers and infiltration of myeloid cells are commonly associated with type 2 immunity, but the roles of these cells and the mechanisms involved in the positive or negative regulation of type 2 inflammation are not fully understood.

In this Special Issue, we invite authors to contribute original research articles as well as review articles on the roles of mast cells and other myeloid cells (i.e., basophils, eosinophils, neutrophils, monocytes, macrophages, and dendritic cells) in the regulation of type 2 immune responses. We especially welcome original research using animal models or *in vitro* models, as well as clinical studies about type 2 immune responses and type 2-mediated allergic disorders.

Potential topics include but are not limited to the following:

- ▶ Contribution of myeloid cells to the positive or negative regulation of allergic inflammation (i.e., in the skin, the airways, and the intestine)
- ▶ Contribution of mast cells and other myeloid cells to anaphylaxis
- ▶ Contribution of mast cells and other myeloid cells to host defense
- ▶ Animal models for studying the roles of myeloid cells
- ▶ Clinical studies on type 2 immune-related disorders
- ▶ Characterization of human primary mast cells or other myeloid cells from allergic or parasite-infected subjects

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/jir/rtir/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

**Lead Guest Editor**

Thomas Marichal, University of Liege,  
Liege, Belgium  
*t.marichal@ulg.ac.be*

**Guest Editors**

Nicolas Gaudenzio, University of  
Toulouse, Toulouse, France  
*nicolas.gaudenzio@inserm.fr*

Laurent L. Reber, Institut Pasteur, Paris,  
France  
*laurent.reber@pasteur.fr*

Philipp Starkl, Medical University of  
Vienna, Vienna, Austria  
*philipp.starkl@meduniwien.ac.at*

**Submission Deadline**

Friday, 16 March 2018

**Publication Date**

August 2018